# A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

> **NCT00077857** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 470 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine (Xeloda®)
- **DRUG:** docetaxel (Taxotere®)

## Key facts

- **NCT ID:** NCT00077857
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 470 (ACTUAL)
- **Last updated:** 2013-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077857, "A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00077857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*